Merck Cardiovascular Investor Event 2022

Merck presented its cardiovascular pipeline at an investor event covering heart failure, pulmonary arterial hypertension, thrombosis, and atherosclerosis programs. The presentation included updates on key candidates Verquvo, sotatercept, MK-5475, MK-2060, and MK-0616, with strategic and discovery perspectives from senior R&D leadership.